More than the third batch of national procurement volume, trillion market will start "big waves of sand"

"Pharmaceutical Network Industry Dynamics" not long ago, the Beijing Municipal Health Insurance Bureau issued a notice, requiring medical institutions to the third batch of national collection of varieties to reportMunicipal Procurement Platform will provide the number of medical institutions involved in the 3rd batch of national collection varieties in 2019 for reference, with the exception of other medical institutions that voluntarily participatecovers a total of 52 varieties, based on the published list of varietiesamong them, there are billions of large varieties sold annually, the total estimated size of the industry is close to 60 billion yuanin practice, since the publication of the third batch of national organizations' centralized procurement catalogues of medicines, a number of provinces and municipalities have carried out or concluded the corresponding reporting workaccording to the, so far, 13 provinces (municipalities and autonomous regions) such as Ningxia, Hunan, Hubei, Tibet, Beijing and Guangdong have carried out the third batch of drug reporting, for example, on June 22, Ningxia Drug Centralized Procurement Network issued the Notice on the Reporting of the 3rd Batch of State Organizations for the Collection of Drug-Related Procurement Data for The Range of Varieties, requiring that all levels of medical insurance departments report the work notice in place by June 23; On the same day, the Hunan Provincial Medical Security Bureau issued a Notice on the Reporting of the Third Batch of State-organized Drug Collection Sourcing Ranges Related To Purchase Data, announcing that public health and health institutions at all levels will begin reporting volumesinvolve s86 rules: Lamifd oral resonosis, Anaqua oral resociable dosage form, azacyloin injection, anitrogen flat oral disintegrating tablets, ibuprofen slow release agent form and metformin oral re-release agent type, metformin slow release control release agent type ..In addition, Hunan Province also encourages health insurance fixed-point non-public medical institutions, retail pharmacies voluntarily and truthfully fill inOn June 29,, the Tibet Autonomous Region Drug Procurement Network issued the Notice on the Reporting of the 3rd Batch of State-organized Drug Collection Sourcing Ranges Related To Purchase Data, which requires that the relevant information related to medical institutions be reviewed and submitted to the Medical Insurance Bureau of the Autonomous Region by June 29;from the provinces and cities of the text, the third batch of national harvest has been actively promoted throughout the countryindustry estimates, in mid-July or will be officially launchedit is worth noting that compared with the previous two collections, the third collection involved more than 50 varieties, the coverage significantly expandedin addition to the rules, a new round of collection has also introduced innovative hospital incentives, or from a number of aspects of the impact on enterprisesfirst of all, in the previous several collections, the hospital declared the procurement volume and clinical actual use gap is large, a number of products appear supply shortage phenomenonunder the guidance of this incentive mechanism, the hospital report will be more reasonable, for the production of pharmaceutical companies to provide more accurate guidance, conducive to timely production scheduling, to ensure the stable supply of selected productssecond, the hospital's use of non-selected products will be disqualified from the award, meaning that after the product lost bid has a greater probability will lose all the market, the importance of winning the bid is more prominent, the bidding will be more intense, the cost control of pharmaceutical companies put forward higher requirementsin this context, the scale effect of large pharmaceutical companies, anti-risk ability and other advantages will be further enlarged, widening the gap with small pharmaceutical companies, the industry will present a polarizing situation, while a market battle, price reduction war will also be readythe future, the winning variety and the price reduction will become the focus of attentionin general, the collection is currently promoting the domestic high-quality pharmaceutical enterprises to accelerate the transformation of special formulations and innovative drugs, and constantly reduce the impact of generic drug collection on their own, under the trend of medical reform, which is mainly collected, it is suggested to pay attention to large generic pharmaceutical companies with low market share before collection and integration of formulation-API, product quantity and technical barriers.